BeiGene’s Brukinsa (zanubrutinib) Receives the NICE Recommendation for Adult Patients with Chronic Lymphocytic Leukemia
Shots:
- The NICE has issued a final draft guidance recommending Brukinsa for eligible adult patients with untreated CLL if there is a 17p deletion or TP53 mutation (high risk); untreated CLL without a 17p deletion or TP53 mutation; FCR or bendamustine + rituximab & r/r CLL
- Additionally, zanubrutinib showed superior efficacy and a favorable safety profile in two P-III trials (SEQUOIA) and (ALPINE) in adult patients with CLL
- Brukinsa was approved in 65+ countries, incl. the US, China, EU, Great Britain, Canada, Australia, South Korea, and Switzerland in selected indications and under development for additional indications globally
Ref: Businesswire | Image: BeiGene
Related News:- BeiGene Reports the US FDA Acceptance of sNDA for Brukinsa + Obinutuzumab for Adult Patients with R/R Follicular Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
